US 11,993,586 B2
Crystalline forms of potassium channel modulators
Gregg F. Keaney, Lexington, MA (US); Jun Xu, Cranbury, NJ (US); and Wenfeng Xue, Cranbury, NJ (US)
Assigned to Novartis AG, Basel (CH)
Appl. No. 17/287,907
Filed by Novartis AG, Basel (CH)
PCT Filed Oct. 21, 2019, PCT No. PCT/US2019/057203
§ 371(c)(1), (2) Date Apr. 22, 2021,
PCT Pub. No. WO2020/086456, PCT Pub. Date Apr. 30, 2020.
Claims priority of provisional application 62/748,632, filed on Oct. 22, 2018.
Prior Publication US 2021/0395229 A1, Dec. 23, 2021
Int. Cl. C07D 403/04 (2006.01)
CPC C07D 403/04 (2013.01) [C07B 2200/13 (2013.01)] 13 Claims
 
1. A single crystalline Form B of a compound having structural formula 1:

OG Complex Work Unit Chemistry
wherein the crystalline form is characterized by at least three x-ray powder diffraction peaks at 2 Θ angles selected from 7.2°, 17.7°, 20.1°, 23.3°, and 23.2°.